Indian pharmaceutical company Emcure Pharmaceuticals Limited has completed the acquisition of Quebec-based cosmetics and dermatological products company Cutimed Inc. for CAD $5.05 million, carrying out the deal through its step-down subsidiary Mantra Pharma Inc.
The transaction closed on April 1, 2026, with Mantra Pharma acquiring all of the issued and outstanding shares of Cutimed under a share purchase agreement. Mantra Pharma is itself a subsidiary of Marcan Pharmaceuticals Inc., which in turn is a step-down subsidiary of Emcure Pharmaceuticals. As a result of the deal, Cutimed became a step-down wholly owned subsidiary of Emcure.
Who Is Cutimed
Cutimed is incorporated in Quebec and has operated in the cosmetics and personal care sector since 2011. The company develops and sells dermatological products, including creams, cleansers and lip care items, mainly for the Canadian market. According to the companies, Cutimed reported annual turnover of CAD $2.80 million, with a financial year running from September 1 to August 30.
Immediate Amalgamation
Right after the acquisition closed, Cutimed was amalgamated with Mantra Pharma, effective the same day, April 1, 2026. The amalgamation used the short-form procedure available under Quebec’s Business Corporations Act and involved two companies that were both already wholly owned by Emcure Pharmaceuticals. The companies described the amalgamation as having been conducted on an arm’s length basis.
Emcure said the acquisition and subsequent amalgamation are meant to strengthen its position in Canada’s dermatological and cosmetic products segments and support its broader growth strategy in the Canadian market. The company said consolidating its Canadian operations under one structure is intended to produce operational and administrative efficiencies.
Regulatory Details
Emcure said the transaction required standard compliance steps under applicable Canadian law but did not need any specific government approvals. The company also stated the deal does not qualify as a related party transaction, since neither Emcure’s promoter, its promoter group, nor other group companies had any prior interest in Cutimed. Emcure said there was no change to its own shareholding structure as a result of the acquisition.
This article references reporting from:
